974 results match your criteria Drug-Induced Pulmonary Toxicity


The long-term safety of chronic azithromycin use in adult patients with cystic fibrosis, evaluating biomarkers for renal function, hepatic function and electrical properties of the heart.

Expert Opin Drug Saf 2021 Jun 7:1-5. Epub 2021 Jun 7.

University Medical Center Groningen, Department of Clinical Pharmacy & Pharmacology, University of Groningen, Groningen, The Netherlands.

: Azithromycin maintenance therapy is widely used in cystic fibrosis (CF), but little is known about its long-term safety. We investigated whether chronic azithromycin use is safe regarding renal function, hepatic cell toxicity and QTc-interval prolongation.: Adult CF patients (72 patients using azithromycin for a cumulative period of 364. Read More

View Article and Full-Text PDF

Improving Pulmonary Nano-Therapeutics Using Helical Aerosol Streams - An In-Silico Study.

J Biomech Eng 2021 May 19. Epub 2021 May 19.

Department of Mechanical & Aerospace Engineering, North Carolina State University, Raleigh, North Carolina, NC27695, United States; Joint UNC-NCSU Department of Biomedical Engineering, Raleigh, NC 27695.

The increasing prevalence of pulmonary ailments including asthma, chronic obstructive pulmonary disorder (COPD), lung tuberculosis and lung cancer, coupled with the success of pulmonary therapy has led to a plethora of scientific research focusing on improving the efficacy of pulmonary drug delivery systems. Recent advances in nanoscience and nanoengineering help achieve this by developing stable, potent, inhalable nano-size drug formulations that potentially increase dosages at target sites with significant therapeutic effects. In this study, we numerically analyze a novel methodology of incorporating helical air-nanoparticle streams for pulmonary nano-therapeutics, using a customized version of the open-source computational fluid dynamics (CFD) toolbox OpenFOAM. Read More

View Article and Full-Text PDF

Pulmonary Manifestations of Inflammatory Bowel Disease.

Cureus 2021 Mar 31;13(3):e14216. Epub 2021 Mar 31.

Internal Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.

The frequency of extraintestinal manifestations of inflammatory bowel disease (IBD) is observed in most of the patients. Extraintestinal manifestations of IBD have been implicated in all the anatomic sites of the pulmonary tree, and include airway inflammation of the bronchi and bronchioles and parenchymal inflammation. There is a wide range of pulmonary manifestations in IBD, and most of them look a lot like other diseases. Read More

View Article and Full-Text PDF

The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Front Pharmacol 2020 18;11:630825. Epub 2021 Mar 18.

Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

For advanced non-small cell lung cancer (NSCLC) patients, first-line chemotherapy is the main treatment in the clinic despite its efficacy is limited and adverse effects are always inescapable. Ginsenoside Rg3, an anti-cancer active ingredient by suppressing angiogenesis, has been increasingly widely used as an adjuvant in first-line chemotherapy for advanced NSCLC to optimize treatment in China. However, no comprehensive meta-analyses have been conducted to estimate the efficacy and safety of the therapy combining ginsenoside Rg3 and first-line chemotherapy in advanced NSCLC patients. Read More

View Article and Full-Text PDF

The Role of Hypoxia-Induced Mitogenic Factor in Organ-Specific Inflammation in the Lung and Liver: Key Concepts and Gaps in Knowledge Regarding Molecular Mechanisms of Acute or Immune-Mediated Liver Injury.

Int J Mol Sci 2021 Mar 8;22(5). Epub 2021 Mar 8.

Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD 21287, USA.

Hypoxia-induced mitogenic factor (HIMF), which is also known as resistin-like molecule α (RELM-α), found in inflammatory zone 1 (FIZZ1), or resistin-like alpha (retlna), is a cysteine-rich secretory protein and cytokine. HIMF has been investigated in the lung as a mediator of pulmonary fibrosis, inflammation and as a marker for alternatively activated macrophages. Although these macrophages have been found to have a role in acute liver injury and acetaminophen toxicity, few studies have investigated the role of HIMF in acute or immune-mediated liver injury. Read More

View Article and Full-Text PDF

Improvement of the pharmacokinetic characteristics of liposomal doxorubicin using CD47 biomimickry.

J Pharm Pharmacol 2021 Mar;73(2):169-177

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Objectives: In view of their biodegradability, biocompatibility, encapsulation efficiency and targeted release, as well as low toxicity, liposomes are being widely used in the context of drug delivery. However, the efficiency of such drug delivery systems might face limitations by macrophage-mediated clearance (CL), which reduces circulation half-life (T½). This problem can be resolved through surface functionalization via poly (ethylene glycol) (PEG) in the process of PEGylation. Read More

View Article and Full-Text PDF

Usefulness of plasmapheresis in patients with severe complicated thyrotoxicosis.

Proc (Bayl Univ Med Cent) 2020 Dec 14;34(2):279-282. Epub 2020 Dec 14.

Division of Internal Medicine/Endocrinology, Texas Tech University Health Science Center, Lubbock, Texas.

The standard treatment of complicated thyrotoxicosis and thyroid storm with the concomitant use of antithyroid medication, iodine, beta-blockers, and corticosteroids is successful in most cases. However, treatment options are limited when antithyroidal drugs cannot be used or in cases that are refractory to standard treatment. Plasmapheresis provides a safe and effective strategy when initial treatment fails, facilitating the transition to definitive treatments such as thyroidectomy. Read More

View Article and Full-Text PDF
December 2020

[Sertraline-induced chronic eosinophilic pneumonia].

Rev Mal Respir 2021 Feb 10;38(2):210-214. Epub 2021 Feb 10.

Service d'anatomopathologie, universitair ziekenhuis Leuven-Gasthuisberg, 3000 Leuven, Belgique.

Introduction: Sertraline is a selective serotonin reuptake inhibitor which is often used as first-line treatment for depression. Several patterns of interstitial lung disease attributable to sertraline have been reported in the literature.

Case Report: A 69-year-old patient, who had been taking sertraline to treat severe depression for 10 months, presented with a deterioration in his general condition and respiratory symptoms found to be associated with bilateral pneumonitis. Read More

View Article and Full-Text PDF
February 2021

Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib.

Toxicol Lett 2021 Jun 8;343:1-10. Epub 2021 Feb 8.

College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing, 211816, China. Electronic address:

Aims: Both gefitinib and afatinib are epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI) in the treatment of non-small cell lung cancer (NSCLC). It has been reported that gefitinib and afatinib could cause hepatotoxicity during the clinic treatment, therefore it is critical to investigate their hepatotoxicity systematically. In this study, zebrafish (Danio rerio) were used as model animals to compare the hepatotoxicity and their toxic mechanism. Read More

View Article and Full-Text PDF

Studies on the safety and the tissue distribution of inhaled high-dose amorphous and crystalline rifampicin in a rat model.

Int J Pharm 2021 Mar 2;597:120345. Epub 2021 Feb 2.

School of Pharmacy, University of Otago, Dunedin, New Zealand. Electronic address:

Inhaled delivery of rifampicin has the potential to achieve high drug concentrations in the lung and the blood for efficient treatment of tuberculosis (TB). Due to its existence as polymorphs, in vivo evaluation of the respiratory tract safety of inhalable amorphous and crystalline rifampicin particles, at clinically relevant high-dose, is necessary. This study investigates the lung and liver safety and the tissue distribution of rifampicin after intra-tracheal administration of high (≥25 mg/kg) doses of amorphous and crystalline powder formulations to Sprague Dawley rats. Read More

View Article and Full-Text PDF

Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane.

Int Immunopharmacol 2021 Apr 30;93:107404. Epub 2021 Jan 30.

Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Medical Oncology, 6525 GA Nijmegen, the Netherlands.

Background: The mTOR inhibitor everolimus used in cancer has immune-modulating effects, potentially contributing to an antitumor response but also leading to pulmonary toxicity. We studied the association of immunological cell subsets with antitumor response and pulmonary toxicity in breast cancer patients treated with everolimus plus exemestane.

Methods: In this exploratory analysis, peripheral blood mononuclear cells (PBMCs) were collected at baseline and 14, 35, 60, and 90 days after start of treatment, and at the moment of pulmonary toxicity. Read More

View Article and Full-Text PDF

Bortezomib induced pulmonary toxicity: a case report and review of the literature.

Am J Blood Res 2020 15;10(6):407-415. Epub 2020 Dec 15.

Department of Hematology, School of Medicine, Koç University Istanbul, Turkey.

Bortezomib is widely used in the treatment of Multiple Myeloma. While the most common side effects are neurological and gastrointestinal related complications, severe pulmonary problems are rarely described. The present case is a 72-year old male with multiple myeloma, who received Lenalidomide, Bortezomib, and Dexamethasone (RVD) combination regimen. Read More

View Article and Full-Text PDF
December 2020

Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience.

Korean J Intern Med 2021 May 8;36(3):689-698. Epub 2021 Jan 8.

Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.

Background/aims: A better understanding of cancer cell biology has led to the discovery and development of several new targeted agents for cancer. These drugs are widely used in cancer treatment and have good toxicity profiles. However, some patients are extremely sensitive to these drugs and can develop severe toxicities. Read More

View Article and Full-Text PDF

Imaging Biomarkers in Animal Models of Drug-Induced Lung Injury: A Systematic Review.

J Clin Med 2020 Dec 30;10(1). Epub 2020 Dec 30.

Department of Translational Medicine, Medical Radiation Physics, Lund University, 20502 Malmö, Sweden.

For drug-induced interstitial lung disease (DIILD) translational imaging biomarkers are needed to improve detection and management of lung injury and drug-toxicity. Literature was reviewed on animal models in which in vivo imaging was used to detect and assess lung lesions that resembled pathological changes found in DIILD, such as inflammation and fibrosis. A systematic search was carried out using three databases with key words "Animal models", "Imaging", "Lung disease", and "Drugs". Read More

View Article and Full-Text PDF
December 2020

Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients.

J Cancer Res Clin Oncol 2021 Mar 2;147(3):725-737. Epub 2021 Jan 2.

Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.

Purpose: Crizotinib is the first-line small molecule tyrosine kinase inhibitor for ALK-positive non-small cell lung cancer. In this study, a retrospective pharmacogenomics investigation was conducted to explore the relationship between genes related to RTK downstream signaling pathways and crizotinib-induced hepatic toxicity in ALK-positive NSCLC patients.

Methods: The variable importance analysis of random forest algorithm was applied to identify the significant features which contribute to the crizotinib sensitivity in Cancer Cell Line Encyclopedia (CCLE) database. Read More

View Article and Full-Text PDF

Longitudinal Imaging Using PET/CT with Collagen-I PET-Tracer and MRI for Assessment of Fibrotic and Inflammatory Lesions in a Rat Lung Injury Model.

J Clin Med 2020 Nov 18;9(11). Epub 2020 Nov 18.

Department of Medical Radiation Physics, Institution of Translational Medicine, Faculty of Medicine, Lund University, 20502 Malmö, Sweden.

Non-invasive imaging biomarkers (IBs) are warranted to enable improved diagnostics and follow-up monitoring of interstitial lung disease (ILD) including drug-induced ILD (DIILD). Of special interest are IB, which can characterize and differentiate acute inflammation from fibrosis. The aim of the present study was to evaluate a PET-tracer specific for Collagen-I, combined with multi-echo MRI, in a rat model of DIILD. Read More

View Article and Full-Text PDF
November 2020

Anticancer Properties of Lobetyolin, an Essential Component of Radix Codonopsis (Dangshen).

Authors:
Christian Bailly

Nat Prod Bioprospect 2021 Apr 7;11(2):143-153. Epub 2020 Nov 7.

OncoWitan, 59290, Lille (Wasquehal), France.

Lobetyolin (LBT) is a polyacetylene glycoside found in diverse medicinal plants but mainly isolated from the roots of Codonopsis pilosula, known as Radix Codonopsis or Dangshen. Twelve traditional Chinese medicinal preparations containing Radix Codonopsis were identified; they are generally used to tonify spleen and lung Qi and occasionally to treat cancer. Here we have reviewed the anticancer properties of Codonopsis extracts, LBT and structural analogs. Read More

View Article and Full-Text PDF

A rare case of nitrofurantoin-induced acute lung injury.

Clin Case Rep 2020 Oct 16;8(10):2029-2033. Epub 2020 Sep 16.

Department of Family Medicine Garnet Health Medical Center Middletown New York USA.

Nitrofurantoin is a common treatment for urinary tract infections. Acute lung injury resulting from nitrofurantoin is a rare, life-threatening complication with women being at greater risk. Symptoms include respiratory distress with fevers, rash, eosinophilia, and new-onset atrial fibrillation. Read More

View Article and Full-Text PDF
October 2020

Comprehensive assessment of side effects in COVID-19 drug pipeline from a network perspective.

Food Chem Toxicol 2020 Nov 21;145:111767. Epub 2020 Sep 21.

Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China; Lerner Research Institute, Cleveland Clinic, Cleveland, USA. Electronic address:

Currently, coronavirus disease 2019 (COVID-19), has posed an imminent threat to global public health. Although some current therapeutic agents have showed potential prevention or treatment, a growing number of associated adverse events have occurred on patients with COVID-19 in the course of medical treatment. Therefore, a comprehensive assessment of the safety profile of therapeutic agents against COVID-19 is urgently needed. Read More

View Article and Full-Text PDF
November 2020

Nitrofurantoin-Induced Pulmonary Toxicity: Always Review the Medication List.

Cureus 2020 Aug 17;12(8):e9807. Epub 2020 Aug 17.

Department of Pulmonary and Critical Care Medicine, San Antonio Uniformed Services Health Education Consortium, Joint Base San Antonio-Fort Sam Houston, USA.

Use of nitrofurantoin for uncomplicated cystitis and recurrent urinary tract infections is common practice. While the majority of patients tolerate this medication without issue, it is important to be cognizant of adverse reactions, as these can impact patient's quality of life. Nitrofurantoin-induced pulmonary toxicity is a rare side effect that can present with various clinical manifestations, imaging abnormalities, and pathologic findings. Read More

View Article and Full-Text PDF

Tiron protects against nicotine-induced lung and liver injury through antioxidant and anti-inflammatory actions in rats in vivo.

Life Sci 2020 Nov 13;260:118426. Epub 2020 Sep 13.

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

Aims: Tobacco smoking is a major health problem associated with lung and liver damage. Lung and liver damage secondary to tobacco smoking is mediated through nicotine-induced oxidative stress. Therefore, we hypothesized that antioxidant treatment with tiron may improve nicotine-induced lung and liver damage. Read More

View Article and Full-Text PDF
November 2020

Incident pulmonary arterial hypertension associated with Bosutinib.

Pulm Circ 2020 Jul-Sep;10(3):2045894020936913. Epub 2020 Aug 21.

Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Pulmonary arterial hypertension is associated with tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia. Dasatinib is a known cause of drug-induced pulmonary arterial hypertension. There have been case reports linking Bosutinib with deterioration of pre-existing pulmonary arterial hypertension. Read More

View Article and Full-Text PDF

[Changes of serum markers in acute liver injury induced by oral 1, 2-dichloropropane in BALB/cA-nu mice].

Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2020 Aug;38(8):602-605

Shanghai Pulmonary Hospital, Shanghai 200433, China.

To investigate the characteristics of inflammatory response in BALB/cA-nu mice induced by oral 1, 2-dichloropropane (1, 2-DCP) , and to provides theoretical reference for further study of subchronic, chronic toxicity and carcinogenic mechanism. From October 2018, Clean grade healthy BALB/cA-nu mice were randomly divided into 5 groups with 10 mice in each group. And 860, 1150, 1500, 1950, 2535 mg/kg 1, 2-DCP were given by gavage respectively. Read More

View Article and Full-Text PDF

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.

Support Care Cancer 2020 Dec 3;28(12):6145-6157. Epub 2020 Sep 3.

Department of Immunology, Faculty of Health Sciences, University or Pretoria, Corner Doctor Savage Road and Bophelo Road, Pretoria, 0002, South Africa.

The immune checkpoints associated with the CTLA-4 and PD-1 pathways are critical modulators of immune activation. These pathways dampen the immune response by providing brakes on activated T cells, thereby ensuring more uniform and controlled immune reactions and avoiding immune hyper-responsiveness and autoimmunity. Cancer cells often exploit these regulatory controls through a variety of immune subversion mechanisms, which facilitate immune escape and tumor survival. Read More

View Article and Full-Text PDF
December 2020

Interstitial pneumonitis in the COVID-19 era: a difficult differential diagnosis in patients with lung cancer.

Tumori 2021 Jun 26;107(3):267-269. Epub 2020 Aug 26.

Division of Thoracic Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

In this coronavirus 2019 (COVID-19) era, when pneumonitis occurs in patients with lung cancer receiving immune checkpoint inhibitors (ICIs), a major challenge is to make a rapid and correct differential diagnosis among drug-induced pulmonary toxicity, tumour progression, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced pneumonitis. While waiting for polymerase chain reaction (PCR) testing results, an accurate evaluation of the symptoms and serologic features can help us make a first diagnostic hypothesis and quickly start correct treatment. Physicians need a collaborative effort to develop and share a common database reporting clinical (anosmia, dysgeusia), serologic, and radiologic data in ICI-treated patients with lung cancer developing interstitial disease to create an evidence-based clinical diagnostic algorithm. Read More

View Article and Full-Text PDF

Everolimus-induced pneumonitis in neuroendocrine neoplasms: correlation of CT findings and clinical signs.

Acta Radiol 2020 Aug 20:284185120950100. Epub 2020 Aug 20.

Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Background: Everolimus, a mammalian target of rapamycin (mTOR)-inhibitor, is approved for the treatment of advanced neuroendocrine neoplasms (NEN). A rare major adverse event is the occurrence of drug-induced pneumonitis.

Purpose: To evaluate the correlation between clinical signs and computed tomography (CT) findings in everolimus-induced pneumonitis in patients with NEN. Read More

View Article and Full-Text PDF

Relationship Between COVID-19 Infection and Liver Injury: A Review of Recent Data.

Authors:
Nurshad Ali

Front Med (Lausanne) 2020 21;7:458. Epub 2020 Jul 21.

Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, Bangladesh.

The COVID-19 outbreak is a great threat to public health worldwide. Lung injury is the main outcome of COVID-19 infection; however, damage can occur in other organs including the liver. Currently, limited data are available that link underlying liver injury with the severe SARS-CoV-2 infection. Read More

View Article and Full-Text PDF

[Protective effects of reduced glutathione on renal toxicity induced by vancomycin in critically ill patients].

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020 Jul;32(7):819-823

Department of Emergency Intensive Care Unit, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Corresponding author: Chen Erzhen, Email:

Objective: To observe the changes of renal function in critically ill patients after using vancomycin and analyze the renal protective effect of reduced glutathione (GSH) on vancomycin nephrotoxicity.

Methods: The clinical data of patients with severe infection who were administered with vancomycin or plus infusion of GSH admitted to intensive care unit (ICU) of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2012 to October 2019 were collected during the study period, and the patients were divided into only vancomycin group and vancomycin combined with GSH group. The gender, age, body weight, underlying diseases, clinical diagnosis, severity score, renal function before and after taking the medicine, average daily dose and treatment duration of vancomycin and GSH, length of ICU stay and clinical outcomes were recorded and analyzed. Read More

View Article and Full-Text PDF

Pulmonary toxicity of systemic lung cancer therapy.

Respirology 2020 11 29;25 Suppl 2:72-79. Epub 2020 Jul 29.

Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Lung cancer is the leading cause of cancer-related deaths worldwide. As new therapies are developed, it is important to understand the pulmonary toxicities associated with systemic lung cancer therapies. Cytotoxic chemotherapy regimens for NSCLC often include taxanes. Read More

View Article and Full-Text PDF
November 2020

Clinical burden of immune checkpoint inhibitor-induced pneumonitis.

Respir Investig 2020 Sep 23;58(5):305-319. Epub 2020 Jul 23.

Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550. Japan. Electronic address:

Immune checkpoint inhibitors (ICIs) have been a breakthrough in medical oncology. However, many patients experience a novel type of adverse drug reaction that has a unique clinical presentation, called immune-related adverse events (irAEs). A breakdown of self-tolerance and an exaggerated autoimmune reaction by the host are assumed to be the underlying mechanisms. Read More

View Article and Full-Text PDF
September 2020